Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of PLSE is 22 and suggests 54% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell